Viridian Therapeutics, Inc./DE APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Viridian Therapeutics, Inc./DE (VRDN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $16.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $16.98M, a 56.62% increase year-over-year.
- Viridian Therapeutics, Inc./DE apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $13.39M, a 31.02% increase year-over-year.
- Viridian Therapeutics, Inc./DE apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $11.25M, a 29.01% increase year-over-year.
- Viridian Therapeutics, Inc./DE apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $10.84M, a 7.84% decline year-over-year.
- Viridian Therapeutics, Inc./DE apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $44.30M, a 5.11% increase from fiscal 2024.
- Viridian Therapeutics, Inc./DE apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $42.15M, a 37.25% decline from fiscal 2023.
- Viridian Therapeutics, Inc./DE apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $67.17M, a 239.85% increase from fiscal 2022.
- Viridian Therapeutics, Inc./DE apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $19.77M, a 36.64% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $16.98M 10-Q · filed 2026-08-06 | $30.37M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $13.39M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $44.30M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $11.25M 10-Q · filed 2025-11-05 | $22.09M derived: sum of 2 quarters · filed 2026-08-06 | $32.31M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $10.84M 10-Q · filed 2026-08-06 | $21.06M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $10.22M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $42.15M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $8.72M 10-Q · filed 2025-11-05 | $20.49M derived: sum of 2 quarters · filed 2025-11-05 | $33.17M derived: sum of 3 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $11.77M 10-Q · filed 2025-11-05 | $24.45M derived: sum of 2 quarters · filed 2025-11-05 | |||
| 2024-03-31 | $12.69M 10-Q · filed 2025-11-05 | ||||
| 2023-12-31 | $67.17M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $13.61M 10-Q · filed 2024-11-12 | $25.91M derived: sum of 2 quarters · filed 2024-11-12 | $41.12M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $12.30M 10-Q · filed 2024-11-12 | $27.52M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $15.22M 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $19.77M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $4.94M 10-Q · filed 2023-11-13 | $9.83M derived: sum of 2 quarters · filed 2023-11-13 | $14.49M derived: sum of 3 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $4.88M 10-Q · filed 2023-11-13 | $9.54M derived: sum of 2 quarters · filed 2023-11-13 | |||
| 2022-03-31 | $4.66M 10-Q · filed 2023-11-13 | ||||
| 2021-12-31 | $14.46M 10-K · filed 2024-02-27 | $14.44M 10-K · filed 2022-03-11 | |||
| 2021-09-30 | $3.98M 10-Q · filed 2022-11-14 | $7.80M derived: sum of 2 quarters · filed 2022-11-14 | $10.97M derived: sum of 3 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $3.82M 10-Q · filed 2022-11-14 | $6.99M derived: sum of 2 quarters · filed 2022-11-14 | |||
| 2021-03-31 | $3.17M 10-Q · filed 2022-11-14 | ||||
| 2020-12-31 | $3.63M 10-K · filed 2022-03-11 | $3.65M 10-K · filed 2021-03-26 | |||
| 2020-09-30 | $615.00K 10-Q · filed 2021-11-05 | $1.24M derived: sum of 2 quarters · filed 2021-11-05 | $1.90M derived: sum of 3 quarters · filed 2021-11-05 | ||
| 2020-06-30 | $623.00K 10-Q · filed 2021-11-05 | $1.29M derived: sum of 2 quarters · filed 2021-11-05 | |||
| 2020-03-31 | $664.00K 10-Q · filed 2021-11-05 | ||||
| 2019-12-31 | $3.97M 10-K · filed 2021-03-26 | ||||
| 2019-09-30 | $874.00K 10-Q · filed 2020-11-12 | $1.95M derived: sum of 2 quarters · filed 2020-11-12 | $2.97M derived: sum of 3 quarters · filed 2020-11-12 | $3.90M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $1.07M 10-Q · filed 2020-11-12 | $2.09M derived: sum of 2 quarters · filed 2020-11-12 | $3.03M derived: sum of 3 quarters · filed 2020-11-12 | $4.00M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-03-31 | $1.02M 10-Q · filed 2020-11-12 | $1.96M derived: sum of 2 quarters · filed 2020-11-12 | $2.92M derived: sum of 3 quarters · filed 2020-11-12 | $3.91M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2018-12-31 | $937.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $1.91M derived: sum of 2 quarters · filed 2020-03-13 | $2.89M derived: sum of 3 quarters · filed 2020-03-13 | $3.68M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $968.00K 10-Q · filed 2019-11-08 | $1.95M derived: sum of 2 quarters · filed 2019-11-08 | $2.74M 10-Q · filed 2018-11-07 | $3.46M derived: sum of 4 quarters · filed 2019-11-08 | |
| 2018-06-30 | $984.00K 10-Q · filed 2019-11-08 | $1.77M 10-Q · filed 2018-08-08 | $2.49M derived: sum of 3 quarters · filed 2019-11-08 | $3.17M derived: sum of 4 quarters · filed 2019-11-08 | |
| 2018-03-31 | $790.00K 10-Q · filed 2019-11-08 | $1.51M derived: sum of 2 quarters · filed 2019-11-08 | $2.19M derived: sum of 3 quarters · filed 2019-11-08 | $2.78M derived: sum of 4 quarters · filed 2019-11-08 | |
| 2017-12-31 | $716.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $1.40M derived: sum of 2 quarters · filed 2019-03-14 | $1.99M derived: sum of 3 quarters · filed 2019-03-14 | $2.41M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $679.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.27M derived: sum of 2 quarters · filed 2017-11-09 | $1.69M 10-Q · filed 2017-11-09 | $450.00K derived: sum of 4 quarters · filed 2018-03-15 | |
| 2017-06-30 | $595.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $1.01M 10-Q · filed 2017-08-11 | -$229.00K derived: sum of 3 quarters · filed 2018-03-15 | -$136.00K derived: sum of 4 quarters · filed 2018-03-15 | |
| 2017-03-31 | $419.00K 10-Q · filed 2017-05-11 | -$824.00K derived: sum of 2 quarters · filed 2018-03-15 | -$731.00K derived: sum of 3 quarters · filed 2018-03-15 | -$96.00K derived: sum of 4 quarters · filed 2018-03-15 | |
| 2016-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$1.15M derived: sum of 2 quarters · filed 2018-03-15 | -$515.00K derived: sum of 3 quarters · filed 2018-03-15 | $198.00K 10-K · filed 2018-03-15 | $2.11M 10-K · filed 2017-03-24 |
| 2016-09-30 | $93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $728.00K derived: sum of 2 quarters · filed 2016-10-26 | $1.44M 10-Q · filed 2016-10-26 | $2.20M derived: sum of 4 quarters · filed 2017-03-24 | |
| 2016-06-30 | $635.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $1.35M 10-Q · filed 2016-08-15 | $2.10M derived: sum of 3 quarters · filed 2017-03-24 | $2.94M derived: sum of 4 quarters · filed 2017-03-24 | |
| 2016-03-31 | $713.00K 10-Q · filed 2016-05-16 | $1.47M derived: sum of 2 quarters · filed 2017-03-24 | $2.31M derived: sum of 3 quarters · filed 2017-03-24 | $3.02M derived: sum of 4 quarters · filed 2017-03-24 | |
| 2015-12-31 | $757.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $1.59M derived: sum of 2 quarters · filed 2017-03-24 | $2.31M derived: sum of 3 quarters · filed 2017-03-24 | $3.02M 10-K · filed 2017-03-24 | |
| 2015-09-30 | $838.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $1.55M derived: sum of 2 quarters · filed 2015-11-13 | $2.26M 10-Q · filed 2015-11-13 | ||
| 2015-06-30 | $712.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $1.42M 10-Q · filed 2015-08-14 | |||
| 2015-03-31 | $708.00K 10-Q · filed 2015-05-15 | ||||
| 2014-12-31 | $4.30M 10-K · filed 2016-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |